to Develop and Accelerate Next-Generation RNA-based Gene-Editing Technology, RetroT™ — Myeloid’s novel RetroT™ technology may enable targeted insertion of gene-sized DNA sequences into the genome, creating new opportunities for programmable gene editing — Myeloid received a $45 million upfront payment from Prime, and is eligible for significant future milestone payments — CAMBRIDGE, Mass, March 31, […]
Late-Breaking Presentations on mRNA in-vivo Delivery and ATAK™ CAR Receptors CAMBRIDGE, Mass., March 9, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it will present two late-breaking posters at the American Association for Cancer Research (AACR) Annual Meeting taking place […]
CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that company management will present a corporate overview at Oppenheimer’s 32nd Annual Healthcare Conference and will participate in one-on-one meetings with investors. The conference is being held in a […]
Daniel Getts, CEO of Myeloid Therapeutics, wants to cure cancer. – – Daniel Getts, CEO of Myeloid Therapeutics, wants to cure cancer. He admits it’s a legitimately bold thing to say, but he has a strong belief that he will make an impact someday. When he walks into his office in Cambridge, Mass., he is […]
Myeloid Therapeutics Appoints Leading Immunologist, Cell & Gene Therapy Expert Bruce McCreedy, Ph.D.
Dr. McCreedy brings decades of executive-level biopharmaceutical experience to advance research and development of novel myeloid-targeting therapies. CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/ — Myeloid Therapeutics, Inc., a clinical-stage immunology company that is combining RNA insights with new technology to develop powerful cancer therapies, today announced that industry veteran Bruce McCreedy, Ph.D., has joined the […]
Industry veteran will draw on unique mix of scientific and business acumen to support Company’s efforts to combat cancer with growing portfolio of novel myeloid-targeting therapies CAMBRIDGE, Mass., March. 31, 2021 /PRNewswire/ — Myeloid Therapeutics, Inc., a clinical-stage immunology company focused on combining RNA insights with cutting edge technologies for new cancer therapies, today announced […]
Myeloid’s cell therapy harnesses the innate capabilities of myeloid lineage cells to fight cancer. Scientific founders include world-renowned cell therapy & cancer experts Ronald Vale, Ph.D. and Siddhartha Mukherjee, M.D., D.Phil. Co-Founded by Thomas Cahill, M.D., Ph.D., with financing led by Newpath Partners and participation from leading biotech investors CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ […]
CAMBRIDGE, Mass., June 2, 2020 – Myeloid Therapeutics, a biotech company harnessing the innate immune system to eradicate cancer and other diseases, today announced a presentation at the Jefferies 2020 Virtual Healthcare Conference. Chief Scientific Officer Daniel Getts, Ph.D., will give a company overview and provide an update on its lead oncology and COVID-19 programs […]